Other grades of this product :
| Lanreotide Acetate Basic information |
| Product Name: | Lanreotide Acetate | | Synonyms: | 10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide;Somatulina;LANREOTIDE ACETATE;3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2→7)-disulfide acetate;Angiopeptin acetate;10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-naphthalen-2-ylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide;Lanreotide Acetate USP/EP/BP;10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)a... | | CAS: | 127984-74-1 | | MF: | C54H69N11O10S2 | | MW: | 0 | | EINECS: | | Product Categories: | Amino Acids & Derivatives, Pharmaceuticals, Intermediates & Derivatives | | Mol File: | 127984-74-1.mol |
| Lanreotide Acetate Chemical Properties |
| Melting point | >165°C (dec.) | | storage temp. | -20°C | | solubility | DMSO (Slightly), Methanol (Slightly) | | form | powder | | color | white to off-white |
| Hazard Codes | Xn | | Risk Statements | 63 | | Safety Statements | 36/37 | | WGK Germany | 3 |
| Lanreotide Acetate Usage And Synthesis |
| Description | Lanreotide acetate, an octapeptide somatostatin analog, reached its first
worldwide market in France for acromegaly when surgery or radiotherapy have
failed to restore normal growth hormone secretion. Lanreotide is a selective inhibitor of
growth hormone and reduces the secretion of growth hormone, thyrotropin, motilin and
pancreatic polypeptide in humans. Lanreotide has antiproliferative properties and is
reportedly in clinical trials for the prevention of restenosis following coronary artery
angioplasty, for diabetic retinopathy, and as a therapy for psoriasis. Its potential for
neuroendocrine tumors and hormone-responsive prostate cancer has also been
demonstrated. | | Originator | Beaufour-Ipsen (France) | | Uses | Lanreotide acetate has been used as an inhibitor to test the plasticity of hydrogen sulfide modulation by growth hormone/thyroid hormone signaling in wild-type mice. | | Uses | Lanreotide Acetate is a drug used in the control and prevention of glycemia and hypoglycemic brain damage without surgery in patients diagnosed with congenital hyperinsulinism. It improves outcomes in patients suffering from acromegalyresulting from invasive pituitary macroadenoma. | | Brand name | Somatuline LP | | Biochem/physiol Actions | Lanreotide acetate is a somatostatin analog, a selective agonist for the SRIF-1 sst2 subtype of somatostatin receptor with a binding affinity of 0.8 nM for sst2 compared to 5.2 nM for sst5, 100 nM for sst3 and more than 1000 nM for the SRIF-2 subtypes, sst1 and sst4 receptors. It is used clinically in the management of acromegaly and symptoms caused by neuroendocrine tumors, and in recent studies can also inhibit tumor growth and has shown activity against non-endocrine tumors. |
| Lanreotide Acetate Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye